3d
GlobalData on MSNFarapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...
Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results